ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF.
Thunnissen E, et al. Among authors: sorensen jb.
Lung Cancer. 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. Epub 2019 Oct 3.
Lung Cancer. 2019.
PMID: 31630043